BioSpace News Archive

Synlogic, Inc. today announced that SYNB1934 was granted Rare Pediatric Disease Designation (RPDD) by the U.S. Food and Drug Administration (FDA) for the potential treatment of phenylketonuria (PKU).

XORTX Therapeutics Inc. is pleased to announce positive topline results from the XRX-OXY-101 – Bridging Pharmacokinetics Clinical Trial.

Nanoscope Therapeutics Inc. today announced that Dr. Samarendra Mohanty , President and Chief Scientific Officer of Nanoscope Therapeutics, will give a presentation titled “Pioneering Laser-Targeted Optical Delivery of Therapeutics to the Eye” and participate in a panel discussion at the Next Generation Ophthalmic Drug Delivery Summit, taking place January 24-26, 2023 in San Francisco.

Apex Labs Ltd. (APEX or the Company), a pharmaceutical company optimizing the standard of mental health care with psilocybin, is pleased to announce its approval by Health Canada to begin APEX-002-A01-03, the world’s largest take home psilocybin clinical trial approved to date.

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorizations for BRUKINSA (zanubrutinib) in Great Britain for both the treatment of adult patients with chronic lymphocytic leukemia (CLL) and the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.

Today, Orbia is proud to announce that the Science Based Targets initiative (SBTi), a partnership between CDP, the United Nations Global Compact, World Resources Institute (WRI) and the World Wide Fund for Nature (WWF), has approved its near-term scope 1, 2 and 3 emissions reduction targets as being in conformance with the latest SBTi Criteria and Recommendations (version 5) for climate actions to mitigate the impacts of global warming.

Normunity, Inc ., a biotechnology company creating novel precision anti-cancer immunotherapies, today announced the appointment of Olga Granaturova, MBA, as Chief Operating Officer and Chief Business Officer.

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced the publication of preclinical proof-of-concept data for its gene therapy candidate for Fabry disease, FLT190, in the Nature journal Gene Therapy.

SAB Biotherapeutics announced that Eddie Sullivan, PhD, co-founder, President and CEO of SAB Biotherapeutics, will present at the 2023 BIO CEO & Investor Conference on Monday, February 6 at 11:15am ET.

Daxor Corporation, the global leader in blood volume measurement technology, announces joining the Heart Failure Society of America as a corporate member to collaborate and deepen engagement with leaders in the field of heart failure.